BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17063439)

  • 1. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
    Infante B; Stallone G; Schena A; Maiorano A; Gesualdo L; Schena FP; Grandaliano G
    G Ital Nefrol; 2006; 23(4):389-95. PubMed ID: 17063439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Skin cancer in renal transplant recipients].
    Mangino M; Schena FP
    G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting malignancy in organ transplant recipients.
    Geissler EK
    Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Minimizing the risk of cancer in transplant patients].
    Campistol JM
    G Ital Nefrol; 2010; 27 Suppl 50():S81-5. PubMed ID: 20922701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A; Schlitt HJ; Geissler EK
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for minimizing immunosuppression in kidney transplantation.
    Kirk AD; Mannon RB; Swanson SJ; Hale DA
    Transpl Int; 2005 Jan; 18(1):2-14. PubMed ID: 15612977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
    Végso G
    Magy Onkol; 2009 Jun; 53(2):149-56. PubMed ID: 19581181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [After care following kidney transplantation].
    Steinhäuslin F
    Schweiz Rundsch Med Prax; 1994 May; 83(22):680-3. PubMed ID: 8016506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New immunosuppressive drugs for prevention and treatment of rejection in renal transplant.
    Segoloni GP; Quaglia M
    J Nephrol; 2006; 19(5):578-86. PubMed ID: 17136684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
    Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
    J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignancy after kidney transplantation: results of 400 patients from a single center.
    Stratta P; Morellini V; Musetti C; Turello E; Palmieri D; Lazzarich E; Cena T; Magnani C
    Clin Transplant; 2008; 22(4):424-7. PubMed ID: 18312442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
    Cantarovich D
    J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bergamo Kidney Transplant Program.
    Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
    Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin cancer in liver transplant recipients.
    Otley CC; Pittelkow MR
    Liver Transpl; 2000 May; 6(3):253-62. PubMed ID: 10827224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
    Ward HJ
    J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.